Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CONMED Corp Director's Dealing 2019

Apr 9, 2019

31971_dirs_2019-04-09_73aa9577-86b2-4466-8a67-f2bc0d5fe3c1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2019-04-08

Reporting Person: Kuyper Dirk (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-04-08 Common Stock M 1000 $33.43 Acquired 13906 Direct
2019-04-08 Common Stock F 406 $82.38 Disposed 13500 Direct
2019-04-08 Common Stock M 1000 $39.64 Acquired 14500 Direct
2019-04-08 Common Stock F 482 $82.38 Disposed 14018 Direct
2019-04-08 Common Stock M 1000 $55.70 Acquired 15018 Direct
2019-04-08 Common Stock F 677 $82.38 Disposed 14341 Direct
2019-04-08 Common Stock S 2000 $83.39 Disposed 12341 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2019-04-08 Sars (Stock Appreciation Rights) $33.43 M 1000 Disposed 2023-07-26 Common Stock (1000) Direct
2019-04-08 Sars (Stock Appreciation Rights) $39.64 M 1000 Disposed 2024-09-11 Common Stock (1000) Direct
2019-04-08 Sars (Stock Appreciation Rights) $55.70 M 1000 Disposed 2025-06-01 Common Stock (1000) Direct

Footnotes

F1: The exercise reported in this Form 4 was effected pursuant to a rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2019.

F2: The exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2019.

F3: The exercise reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2019.

F4: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 6, 2019.

F5: The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting 100% after a one year period.

F6: The stock appreciation rights ("SARs") were granted under the Company's 2007 Amended and Restated Non-Employee Director Equity Compensation Plan, with the SARs generally vesting upon completion of the term of service.